Navigation Links
Breakthrough System for Understanding Ocean Plant Life Announced

Sixty million people in 36 countries of sub-Saharan Africa are threatened daily by a deadly parasitic disease known as African sleeping sickness. The disease is caused by organisms called trypanosomes, which are spread by the tsetse fly. African sleeping sickness affects approximately 500,000 people in sub-Saharan Africa, a quarter of whom will die this year. Because the trypanosome has an exceptional genetic strategy for evading the human immune system and resisting treatment, the current treatment for this disease is melarsopal, an antiquated drug with terrible side effects, including death.

In the February issue (Volume 17, Issue 3) of the journal Molecular Cell, scientists in the Marine Biological Laboratory's (MBL's) Josephine Bay Paul Center for Comparative Molecular Biology and Evolution report their discovery of a protein called JBP2, which will help them test their hypothesis that a uniquely modified DNA base called base J is a key component of the trypanosome's mechanism for evading the immune system. If the hypothesis is correct, it will bring scientists closer to developing a more effective drug for treating African sleeping sickness.

The trypanosome evades the human immune system because it is coated with a surface antigen called variant surface glycoprotein (VSG). The human body makes antibodies for VSG, but trypanosomes randomly switch to another antigen when the organisms divide and reproduce. Trypanosomes whose VSG has switched evade the antibodies the human immune system made to fight the original antigen, thus assuring the long-term survival of these parasites within their hosts. The trypanosome has approximately 1,000 different VSG genes, but only expresses one at a time while the others are somehow silenced. This genetic trick, called antigenic variation, has severely limited sleeping sickness treatment options and essentially ruled out the possibility of a vaccine.

MBL trypanosome experts in Robert Sabatini's lab hypothes
'"/>

Source:


Page: 1 2

Related biology news :

1. Breakthrough Microarray-based Technology for the Study of Cancer
2. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
3. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
4. Breakthrough isolating embryo-quality stem cells from blood
5. Breakthrough: Scientists create worlds tiniest organic particles
6. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
7. Sciences Breakthrough of the Year: Watching evolution in action
8. Breakthrough for stem cell research
9. Breakthrough in understanding type-2 diabetes as key genes identified
10. Breakthrough vaccine to treat chemo-resistant ovarian cancer
11. Genes In The Interferon System Important In Systemic Lupus Erythematosus
Post Your Comments:
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Washington University in St. Louis is the mastermind behind a ... children but appealing to all ages, on an endangered species ... in Arts & Sciences, is the driving force behind ... Bonobo , written by Mathea Levine, Goodenough,s daughter, and featuring ...
... may have a big role in helping you make more ... parallel, and the idea is if you can somehow disrupt ... Dr. Xingming Shi, bone biologist at the Medical College of ... the short-acting protein GILZ appears to make this desirable shift ...
... of life-threatening diseases but they also are becoming increasingly ... people, scientists among them, are largely unaware of the ... Research on fungi and fungal diseases are seriously neglected ... negative repercussions for human health, agriculture, and the environment-- ...
Cached Biology News:Book's plea: Save the bonobos 2Book's plea: Save the bonobos 3Book's plea: Save the bonobos 4Small protein may have big role in making more bone and less fat 2Small protein may have big role in making more bone and less fat 3Fungi the cause of many outbreaks of disease but mostly ignored 2Fungi the cause of many outbreaks of disease but mostly ignored 3
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies announced ... is joining its Board of Director as Chair of ... at Zillow Group, Chad oversees all finance, treasury and ... the company,s core finance, treasury and accounting functions, and ... nine acquisitions. In 2013, he was named Puget Sound ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... HubCast® Inc. ( http://www.hubcast.com ), the ... expansion of its Global Print Supply Chain with next-day ... world’s largest cities across 75 countries globally. The ... providing global enterprises ease, speed, reach, quality, cost savings ... order to real-world delivery at postal address around the ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4
... of Unsaturated Fatty Acids in ... Cardiovascular ... AMRN ) today announced that it has initiated a cardiovascular,development ... acids in cardiovascular disease. Amarin plans to utilize,its extensive know-how ...
... Fourth Fourth Fiscal ... Year ... seed and traits $364 $212 $2,807 $1,793 ... 960 Cotton seed and traits 58 ...
... Fats, Uses No Water, Produces Pure Glycerin, ... Inc., a,new-generation biodiesel refining and distribution company, announced ... biodiesel refinery,leveraging a novel solid catalyst that converts ... planned to be located in Seymour,Ind., eliminates the ...
Cached Biology Technology:Amarin Announces Initiation of Cardiovascular Development Strategy 2Amarin Announces Initiation of Cardiovascular Development Strategy 3Amarin Announces Initiation of Cardiovascular Development Strategy 4Amarin Announces Initiation of Cardiovascular Development Strategy 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 2Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 3Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 4Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 6Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 7Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 8Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 9Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 10Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 11Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 12Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 13Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 14Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 15Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 16Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 17Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 18New Benefuel Refinery Targets Key Flaws in Biodiesel Production 2New Benefuel Refinery Targets Key Flaws in Biodiesel Production 3
... yield technology is fast - 2 hour ... gene array analysis , Efficiently ... Kits specific for templates with T7, T3 ... , All kits contain SUPERaseIn Ribonuclease Inhibitor ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide ... human PDGF-D (platelet derived growth factor D ... protein which differs from mouse and rat ... Reacts with the ~50 kDa human mouse ...
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
Biology Products: